Affidea teams up with b-rayZ for advanced AI solutions in breast imaging technology
## Revolutionizing Breast Cancer Diagnostics: b-rayZ's AI Solutions Transform Affidea's Network
b-rayZ, a pioneer in AI-powered breast imaging solutions, is making a significant impact on patient outcomes, particularly within the Affidea Group. This partnership is set to redefine breast cancer diagnostics and improve early detection and outcomes across Europe.
### Strategic Collaboration with Affidea
The strategic alliance between b-rayZ and Affidea, a leading pan-European provider of specialist healthcare services, has seen Affidea invest in b-rayZ's Series A extension equity funding round. This collaboration marks a significant milestone in b-rayZ's journey and validates their vision and growth strategy[2][3].
### Implementation Across Affidea Centers
b-rayZ's AI technology is already in use at several Affidea locations, including the Centre of Excellence in Breast Cancer, Brust Zentrum Zurich in Switzerland, and Givision at Hôpital Daler. It has also been successfully implemented in Lithuania and Spain, with plans for further expansion across other Affidea countries offering breast imaging services[1][3].
### Enhancing Diagnostic Precision and Patient Care
b-rayZ's AI platform is designed to streamline the diagnostic process, reducing fragmentation and ensuring a more precise and timely diagnosis. By standardizing and elevating diagnostic quality across diverse clinical environments, b-rayZ supports Affidea's mission to improve early detection and outcomes in breast cancer[1][3].
Dr. Alessandro Roncacci, SVP and Chief Medical Officer at Affidea, stated that the partnership aims to integrate AI to enhance sub-specialty breast imaging, improve diagnostic accuracy, and optimize personalized screening pathways. The collaboration with b-rayZ is aimed at redefining breast cancer diagnostics[4].
### A New Era for Breast Cancer Diagnostics
The partnership between Affidea and b-rayZ is expected to lead to earlier diagnoses, reduce variability in interpretations, and ensure the best possible clinical outcomes for women across Europe. This investment positions Affidea to accelerate innovation across its network by integrating AI across its network[3][5].
Cristina Rossi, CEO and founder of b-rayZ, stated that the company is deeply committed to preserving women's health and designing AI solutions to provide the highest level of diagnostic accuracy and efficiency tailored to each woman's needs. Through this partnership, Affidea is integrating AI to improve diagnostic accuracy in the highly specialized field of breast imaging[4].
The strategic alliance between Affidea and b-rayZ plans to further develop AI solutions, empower radiologists, optimize clinical workflows, and improve patient care, setting a new standard for breast cancer diagnostics across Europe.
- The AI solutions provided by b-rayZ, such as those currently in use at the Centre of Excellence in Breast Cancer and Givision at Hôpital Daler, aim to improve diagnostic precision and enhance patient care in the field of breast cancer.
- The partnership between b-rayZ and Affidea is not only expected to lead to earlier diagnoses for women across Europe, but also promises to reduce variability in interpretations and ensure the best possible clinical outcomes.
- The collaboration between these two entities marks a significant leap towards incorporating artificial intelligence into medical-conditions like breast cancer, as part of Affidea's health-and-wellness strategy.
- As breast cancer is one of the most prevalent medical-conditions among women, this strategic alliance between b-rayZ and Affidea is a crucial step in revolutionizing science and technology related to women's health, particularly breast cancer diagnostics.
